Raziel and Fosun Pharma (by JuveStar an affiliate company of Fosun Pharma) Initiate Phase 3 Registration Trial in China for Submental Fat Reduction (“double chin”)
REROVOT, Israel, March 4, 2025 /PRNewswire/ -- Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces phase 3 study initiation in China for the treatment of fat reduction in the submental area. Submental fat (SMF) reduction is the first indication for RZL-012 among many potential aesthetic focal fat reduction treatments for body shaping....
WuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production
- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of non-monoclonal antibody (non-mAb) recombinant proteins and plasmid DNA for clients across the globe - EffiX™ delivers high-yield production across multiple modalities, achieving titers of over 15 g/L for...
CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody
SUZHOU, China, March 4, 2025 /PRNewswire/ --CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient has been successfully dosed in the global multicenter Phase I clinical trial of its novel PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, with no infusion reactions or other adverse events observed. This...
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
MELBOURNE, Australia and INDIANAPOLIS, Ind., March 4, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the Company's late-stage and next-generation radiotherapeutic candidates in urologic oncology. In this education session, Telix and global key opinion leaders will provide an overview on...
Apply Now for The Sigourney Award-2025 Honoring Outstanding Psychoanalytic Work Around The World
SAN FRANCISCO, March 3, 2025 /PRNewswire/ -- The Sigourney Award Trust is accepting applications and nominations for The Sigourney Award-2025 now through July 31st. The prestigious, wholly independent prize celebrates 35 years of recognizing work by individuals, teams, and organizations from around the world who have advanced psychoanalytic thought, principles and practice....
Frost & Sullivan Recognizes Cynerio for Advancing Healthcare Cybersecurity with Its NDR-H Solution to Combat Cyber Threats
Cynerio's NDR-H Solution enables deep packet inspection, comprehensive network traffic analysis with real-time threat detection and response, and proactive auto identification and analysis of connected devices. SAN ANTONIO, March 3, 2025 /PRNewswire/ -- Frost & Sullivan recently analyzed the healthcare security industry and, based on its assessment, recognizes Cynerio with the 2025 North American Enabling Technology Leadership Award. Realizing just...
Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept
Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience Financing led by Frazier Life Sciences with significant participation from Jeito Capital alongside other life sciences investors including Novo Holdings A/S, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and...
DrFirst Recognized for Enabling Technology Leadership in Healthcare by Frost & Sullivan
Leading the Way in Healthcare Innovation Across the Medication Journey SAN ANTONIO, March 3, 2025 /PRNewswire/ -- DrFirst, a leading innovator in healthcare technology, has been honored with the prestigious Enabling Technology Leadership Award by Frost & Sullivan. This recognition highlights how the outstanding contributions of DrFirst bridge critical gaps in healthcare through groundbreaking technology solutions. With its comprehensive...
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat’s Gut Microbiome Effects from Other Anti-CDI Antibiotics
First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat (IBZ) to other anti-CDI antibiotics in a germ-free mouse model Changes in alpha and beta microbiome diversities following IBZ treatment were less pronounced compared to those observed in vancomycin (VAN)-or metronidazole (MET)-treated groups, complementing prior Phase 2 clinical findings showing IBZ's more selective antibacterial activity Notable...
Transforming Tianhe: A Vision for Modern Industries
BEIJING, March 3, 2025 /PRNewswire/ -- A news report from chinadaily.com.cn： A panoramic view of the skyscrapers of Tianhe district. Tianhe district, Guangzhou's leading economic powerhouse, is prioritizing the development of eight strategic industry clusters, four future industries, and six modern service industries as its approach to high-quality development. The district announced its...
